Abstract 672P
Background
Open sharing of synthetic trial data could facilitate secondary analyses and synthetic control arm development.
Methods
This study included 128 experimental vs. control treatments for solid tumors from 115 phase 3 randomized clinical trials (RCTs) published in 7 high-impact journals in 2023. Original individual patient data were reconstructed from the published Kaplan-Meier curves of overall survival (OS) in the intention-to-treat population. Either both arms (fully synthetic; retaining original sample size) or only the control arm (partially synthetic; retaining original control arm size) were synthesized using statistical models (Weibull and Synthpop) and a deep generative model (SurvivalGAN). Original and synthetic RCTs were compared through the probability overlap (0: none, 1: perfect) of the 95% confidence intervals (CIs) for the hazard ratio (HR), and the true (TPR) and false positive rate (FPR) with respect to the direction of the HR and its statistical significance on the 0.05 level.
Results
The median sample size was 571 (range 82-5637) and the median HR for OS was 0.80 (range 0.39-1.14) in the original (reconstructed) RCTs. Fifty-six (43.8%) were statistically significant, all of which showing superiority of the experimental treatment. The results presented in the table indicate that the use of synthetic arms may introduce bias due to generative model misspecification (in particular for fully synthetic RCTs created by Weibull) and additional variability inherent to the data generating process (more pronounced in fully vs. partially synthetic RCTs and in deep generative vs. statistical models), leading to insufficient CI overlap for the HR and thereby impacting statistical inference. TPR ranges from 2.6% to 80.4% and 90.9% to 98.2% in fully and partially synthetic RCTs, while FPR ranges from 25.0% to 46.4% and 27.8% to 44.4%, respectively. Table: 672P
Results of the synthetic RCTs
Approach | Model | Difference in log HR: mean (sd) | 95% CI overlap: mean (sd) | TPR: % | FPR: % |
Full | Weibull | 0.33 (0.43) | 0.43 (0.39) | 2.6 | 29.5 |
Full | Synthpop | 0.01 (0.20) | 0.84 (0.20) | 80.4 | 25.0 |
Full | SurvivalGAN | -0.01 (0.73) | 0.46 (0.35) | 66.0 | 46.4 |
Partial | Weibull | -0.11 (0.15) | 0.81 (0.23) | 90.9 | 32.4 |
Partial | Synthpop | -0.10 (0.25) | 0.85 (0.26) | 96.4 | 27.8 |
Partial | SurvivalGAN | -0.14 (0.23) | 0.71 (0.31) | 98.2 | 44.4 |
Conclusions
Naive inference from RCTs with synthetic arms may lead to overly optimistic or even wrong conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ghent University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01